The Pro Medicus Limited (ASX: PME) share price has started the week in fine form.
At the time of writing the health imaging software company’s shares are up 2% to $23.95.
Why is the Pro Medicus share price on the rise?
Investors have been buying Pro Medicus’ shares on Monday after the release of a positive announcement.
According to the release, Pro Medicus’ wholly owned U.S. subsidiary, Visage Imaging, has signed a five-year, multi-million dollar contract with Palo Alto based Nines.
Nines aims to help radiologists give customers exceptional service, quality, and access. It unites radiologists and engineers in-house to build modern quality tools for exceptional patient care.
It was co-founded by CEO David Stavens PhD, a highly respected Silicon Valley inventor and entrepreneur, and CMO Alexander Kagen, the Site Chair of Radiology at Mount Sinai’s West and St. Luke’s Hospitals in New York City.
Today’s agreement will see the creation of an offering, based on Visage 7 technology, hosted on the Google Cloud Platform and will provide Nines with an immensely scalable and highly optimised platform.
Pro Medicus CEO, Dr Sam Hupert, was very pleased with the agreement.
He said: “This is an extremely exciting opportunity for us. The team behind Nines are incredibly well known and respected in machine learning, AI, and radiology circles. Partnering with them will allow us to support their efforts to develop future products with our highly optimised Visage 7 cloud-based solution for on-demand reads.”
The five-year contract is based on committed exam volumes that step up year-on-year aligning with projected growth of the Nines offering in the market.
This will result in base revenue to Pro Medicus in excess of A$6 million over the life of the contract with the potential for significant upside.
Implementation will begin in the next few weeks. After which, it is expected to go live in the second quarter of the 2020 calendar year.
Nines’ David Stavens, commented: “Leading healthcare institutions expect high-quality radiology reports 24/7. Visage and Nines are collaborating on a modern cloud-based service with an eye toward exceeding those expectations.”
“Radiologists face increasingly complex workloads. At Nines we aim to provide the best technology to help radiologists diagnose efficiently while prioritizing their time for the patients who need it most. Nines selected Visage for its tech-focused leadership and we’re excited to offer Visage 7 as part of our scalable solution,” he concluded.
The post Pro Medicus share price higher on deal with Palo Alto based Nines appeared first on Motley Fool Australia.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019